Australia markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.08+0.27 (+3.06%)
At close: 04:00PM EST
9.13 +0.05 (+0.55%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.81
Bid8.96 x 900
Ask9.13 x 800
Day's range8.46 - 9.46
52-week range2.84 - 45.00
Avg. volume12,843,904
Market cap189.326M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Here's Why Longeveron Stock Jumped Higher on Wednesday

    Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.

  • Motley Fool

    Is It Too Late to Buy Longeveron Stock?

    Up nearly 400% in the last month alone, Longeveron (NASDAQ: LGVN) is doubtlessly one of the more volatile biotechs in the longevity space. Between its brief dalliance with meme stock traders in November and recent progress with regulatory authorities, plenty of people have made a lot of money on the stock. The key fact for investors to know about Longeveron is that it's a young biotech without any late-stage projects.

  • Motley Fool

    Why Longeveron Stock Skyrockted 661.2% in November

    Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.